Normal erythrocyte calpain I activity on membrane proteins under near-physiological conditions in patients with essential hypertension.
BACKGROUND
It has been reported that the equilibrium between the erythrocyte protease calpain I and its physiological inhibitor calpastatin is disrupted in patients with essential hypertension.


OBJECTIVE
To investigate the activity of non-purified calpain I in hemolysates against the erythrocytic membrane proteins, rather than against other substrates.


METHODS
Evaluation of calpain I red cell activity upon its own physiological substrates in hypertensive patients, in a near-physiological environment.


METHODS
LIM-23 and LIM-40 of Hospital das Clinicas of the Faculty of Medicine of USP.


METHODS
Patients with moderate primary hypertension over 21 years of age who were given amlodipine (n:10) and captopril (n:10) for 8 weeks, plus normal controls (n:10).


METHODS
Red cell membrane proteins were incubated with and without protease inhibitors and with and without calcium chloride and underwent polyacrylamide gel electrophoresis.


RESULTS
Digestion of bands 2.1 and 4.1 was observed, indicating calpain I activity. No statistical differences regarding bands 2.1 and 4.1 were observed before treatment, between the controls and the hypertensive patients, either in ghosts prepared without calcium or with increasing concentrations of calcium. Nor were statistical differences observed after treatment, between the controls and the patients treated with amlodipine and captopril, or between the patients before and after treatment with both drugs.


CONCLUSIONS
The final activity of non-purified calpain I upon its own physiological substrate, which was the approach utilized in this study, may more adequately reflect what happens in red cells. Under such conditions no imbalance favoring calpain I activity increase was observed. The protective factor provided by calpastatin against calpain I activity may diminish under hypertension.
Dantas de Medeiros
Tereza Maria
TM
LIM-234 and LIM-40, Hospital das Clinicas, Faculty of medicine, Universidade de São Paulo, São Paulo, Brazil.
Ortega
Katia Coelho
KC
Mion
Décio
D
Nonoyama
Kimiyo
K
Barretto
Orlando Cesar de Oliveira
OC
D000328:Adult; D017311:Amlodipine / Q000627:therapeutic use; D017487:Ankyrins / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002154:Calpain / Q000097:blood / Q000502:physiology*; D002216:Captopril / Q000627:therapeutic use; D016022:Case-Control Studies; D004591:Electrophoresis, Polyacrylamide Gel; D004910:Erythrocyte Membrane / Q000201:enzymology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology*; D008565:Membrane Proteins / Q000097:blood / Q000502:physiology*
C110202:ANK1 protein, human; D017487:Ankyrins; D002135:Calcium-Binding Proteins; D008565:Membrane Proteins; D017311:Amlodipine; C033668:calpastatin; D002216:Captopril; D002154:Calpain